SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing extreme volatility and a sharp sell-off following quarterly earnings that investors are viewing as a 'sell the news' event despite reported growth. The community is actively debating whether the stock is a deep-value buying opportunity or if the current momentum suggests a continued slide, with many traders questioning why the market reaction has been so severe given the company's raised guidance.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is experiencing intense community focus ahead of its quarterly earnings release, with investors closely watching for updates on its Neutron rocket program, defense contract conversions, and revenue growth. Sentiment remains bullish, as market participants look past recent volatility, citing the company's expanding backlog and position as a key strategic partner in the growing space defense and satellite infrastructure sectors.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Atara Biotherapeutics is trending as investors react to a significant regulatory update regarding tabelecleucel, with community discourse divided between optimism over the path to FDA approval and skepticism regarding the company's financial stability and dilution risks. Traders are closely monitoring the stock's volatility and institutional activity, while debating whether the current price action reflects a true recovery or potential downside volatility.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is currently the focus of investor attention as it faces high-stakes earnings after a round of workforce reductions and ongoing debate surrounding the Clarity Act. Market participants are actively weighing concerns about the company's cost structure and competitive positioning against bullish sentiment regarding institutional adoption and its evolving role in financial infrastructure.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is experiencing extreme volatility as investors weigh massive revenue growth and hyperscaler tailwinds against concerns over heavy debt, rising capital expenditures, and significant insider selling ahead of the earnings report. The community remains sharply divided, with bulls betting on a breakout fueled by AI demand, while bears anticipate a post-earnings sell-off due to the company's historical volatility and high burn rate.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing a significant surge in social media activity as investors position themselves ahead of the upcoming earnings release, debating whether the stock will trigger a major short squeeze given its high short interest and institutional accumulation. The community remains sharply divided, with bulls pointing to strong AI growth narratives and potential partnerships, while bears continue to raise concerns regarding the company's path to profitability and recent valuation run-up.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is currently trending as investors weigh strong profitability and recent AAA-rated funding successes against market volatility and geopolitical concerns affecting the fintech sector. While the community is actively debating the stock's long-term valuation potential and the impact of the ongoing leadership transition, sentiment remains divided between those betting on an institutional re-rating and short-term traders reacting to intense short interest.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy is experiencing significant volatility as investors weigh strong revenue growth and a record backlog against concerns regarding tightening profit margins and ongoing cash flow challenges. The community is actively debating the company's position as a key infrastructure provider for AI data centers versus its persistent struggle to achieve consistent bottom-line profitability.

Agilon Health, Inc. engages in the provision of healthcare services. It also provides capital, data, payor relationships, executive experience, and contract support that allow physician groups to take on the risk of total care for their patients. The company was founded by Ronald A. Williams and Veeral Desai in 2016 and is headquartered in Westerville, OH.

Agilon Health Inc

Agilon Health is seeing intense trading volume and community speculation driven by a combination of low-float volatility and aggressive short-squeeze sentiment. Investors are closely tracking institutional positioning and technical momentum, with discussions heavily focused on potential price expansion targets and the stock's ability to maintain high daily trading activity.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is facing intense volatility following its recent earnings report, as investors weigh impressive revenue growth and aggressive expansion plans against concerns over margin compression and a potential slowdown in historical growth rates. The community remains sharply divided, with bulls viewing the pullback as a prime accumulation opportunity for a high-growth brand, while bears argue that the valuation remains too steep relative to the cooling consumer environment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OnKure Therapeutics (NASDAQ:OKUR) Issues Quarterly Earnings Results

OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.37...

CVS Q1 Earnings Preview: Health Services Likely to Lead Performance

CVS Health heads into Q1 earnings results with Health Services growth expected to offset pressure in benefits, as revenues dip slightly and costs remain elevated.

OnKure Therapeutics (OKUR) Projected to Post Quarterly Earnings on Tuesday

OnKure Therapeutics (NASDAQ:OKUR) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-onkure-therapeutics-stock...

Short Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Drops By 57.6%

OnKure Therapeutics, Inc. (NASDAQ:OKUR - Get Free Report) was the target of a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling 69,494 shares, a decrease of 57.6% from the March 31st total of 163,904 shares. Currently, 0.5% of the shares of...

TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?

Thermo Fisher heads into Q1 earnings with Life Sciences Solutions growth in focus, as bioproduction strength and new innovations may drive results.

Short Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Increases By 1,958.6%

OnKure Therapeutics, Inc. (NASDAQ:OKUR - Get Free Report) saw a large increase in short interest in March. As of March 31st, there was short interest totaling 163,904 shares, an increase of 1,958.6% from the March 15th total of 7,962 shares. Based on an average daily volume of 786,389 shares, the...

OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Down 85.2% in March

OnKure Therapeutics, Inc. (NASDAQ:OKUR - Get Free Report) was the target of a significant decline in short interest in March. As of March 13th, there was short interest totaling 7,962 shares, a...

HC Wainwright Has Positive Forecast for OKUR Q1 Earnings

OnKure Therapeutics, Inc. (NASDAQ:OKUR - Free Report) - Stock analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for OnKure Therapeutics in a research note issued to...

OnKure Therapeutics (NASDAQ:OKUR) Price Target Lowered to $27.00 at HC Wainwright

HC Wainwright dropped their price objective on OnKure Therapeutics from $34.00 to $27.00 and set a "buy" rating on the stock in a research report on Monday...

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

OKUR
Onkure Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Compact View

Poll

Latest OKUR News

OKUROnkure Therapeutics Inc